ITHACA, N.Y. — Rheonix Inc., a developer of fully automated molecular testing solutions, raised $14 million in a combination of debt and equity investments to complete a manufacturing build out and launch its first commercial product. The funds will be used to expand the company’s physical operations to produce consumables and systems to fulfill Rheonix’s joint development agreement with Life Technologies Corp. and for the commercialization of its first clinical,… Read More »
With $14 MILLION in debt and equity financing in hand, molecular diagnostics firm Rheonix is planning to expand both its physical footprint and molecular testing product portfolio in the coming year, company president Tony Eisenhut said this week.
First, Rheonix is already in the process of building out new manufacturing facilities just down the street from its current Ithaca, NY, headquarters, primarily to enable it to produce consumables and systems to… Read More »
ITHACA, N.Y. — Genetic testing laboratories currently face constraints such as complex sample preparation, complicated workflow and long waits for test results. Molecular diagnostics executive Richard Montagna, Ph.D., vice president for scientific affairs for Rheonix Inc., an Ithaca-based developer of an automated molecular testing platform, will present ways to overcome some of these challenges and provide cost-effective molecular diagnostics for personalized medicine at an international conference later this month.
“We are… Read More »
ITHACA, N.Y. – Rheonix Inc., a developer of fully automated molecular testing solutions, will address the need for access to critical advanced molecular testing, labor shortages that limit the availability of testing, and other obstacles laboratories face in adoption of this technology at the Association for Molecular Pathology (AMP) 2013 Annual Meeting in Phoenix, Ariz., Nov. 14-16.
Rheonix will display its Chemical and Reagent Device (CARD) and EncompassMDx™ molecular testing platform.… Read More »
ITHACA, N.Y. — Rheonix, Inc., a developer of fully automated molecular testing solutions, has received a $500,000 Small Business Innovation Research (SBIR) Phase IIB grant from the National Science Foundation (NSF). The funding adds to the $650,000 the company previously received in NSF SBIR Phase I, Phase IB and Phase II funding for this project and will allow Rheonix to expand the capabilities of its pathogen detection system from the… Read More »
The development of multiplex companion diagnostics is driven by the need to understand efficacy and safety at both the molecular and phenotypic levels. In the future, personalized therapeutic regimens will be tailored to each patient’s genomic, transcriptomic, and epigenomic profiles to optimize individual outcomes.
For personalized (or precision) medicine to become a sustaining reality, all stakeholders—patients, healthcare professionals, drug development companies, regulatory agencies and payers—must work together.
Advancing multiplex companion diagnostics technology… Read More »
ITHACA, N.Y. – Rheonix, Inc., a developer of fully automated molecular testing solutions, and Life Technologies Corp. (NASDAQ: LIFE), a global leader in the life sciences tools and diagnostic markets, have entered into a joint development agreement to introduce a molecular testing platform for their Applied Markets business.
Technology developed by Rheonix for the molecular diagnostics market, including the Rheonix CARD® , a disposable cartridge the size of a credit card… Read More »
ITHACA, N.Y. – Widespread implementation of personalized medicine will depend upon identification of clinically relevant biomarkers, cost-effective methods to detect them and a reimbursement strategy that will meet the needs of all stakeholders.
These will be a few of the points raised during a workshop entitled “Implementing Effective and Reimbursable Personalized Medicine” at the upcoming joint annual meeting of the American Association for Clinical Chemistry (AACC) and the American Society for… Read More »
ITHACA, N.Y. – The discovery and development of microfluidic sensors hold great promise for the design of revolutionary diagnostic devices capable of complex analysis, in a disposable format, with minimal user intervention. However, many devices in this category have faced challenges to their widespread adoption.
Rheonix Inc., an Ithaca-based developer of an automated molecular testing platform, has successfully navigated the technological hurdles and solved many of the challenges in this area.… Read More »
ITHACA, N.Y. –– Rheonix Inc., developer of automated molecular diagnostic platforms and consumables, has added Frank Gill as vice president of manufacturing. In this role, Gill will be responsible for formulating and executing the company’s operations strategy as it scales from prototype volumes to fully automated production of life science and in vitro diagnostics products.
Gill will oversee manufacturing of Rheonix instrument platforms, reagent kits, and the Rheonix CARD® system, a… Read More »